64 studies found for:    IL2RA
Show Display Options
Rank Status Study
1 Unknown  Comparison of Alemtuzumab/Tacrolimus Versus Interleukin-2 Receptor (IL-2R) Monoclonal Antibody (MoAb)/Tacrolimus/Mycophenolate in Kidney Transplantation
Conditions: Kidney Transplantation;   Kidney Diseases;   Kidney Failure
Interventions: Drug: Alemtuzumab;   Drug: Daclizumab
2 Completed Sequential Therapy (FK506 + Monoclonal Anti-IL2R Antibodies + MMF) Versus FK506 With Steroids in Liver TX
Condition: Liver Transplantation
Interventions: Drug: tacrolimus;   Drug: Anti-IL2R AB;   Drug: Mycophenolate mofetil;   Drug: prednisone
3 Completed Comparing Efficacy and Safety of Tacrolimus With Steroids or Monoclonal Anti-IL2R Antibody in Hepatitis C Virus (HCV) Positive Liver Transplant Patients
Conditions: Hepatitis C;   Liver Transplantation
Interventions: Drug: Tacrolimus;   Drug: steroids, monoclonal anti-IL2R antibody
4 Active, not recruiting Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
Condition: End Stage Renal Disease
Interventions: Drug: Rabbit Antithymocyte globulin;   Drug: Daclizumab
5 Completed Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.
Condition: Liver Transplantation
Intervention: Drug: tacrolimus
6 Completed A Randomized Trial of Recombinant Humanized Anti-IL-2 Receptor Antibody (Daclizumab) Versus Antithymocyte Globulin (ATG) to Treat the Cytopenia of Myelodysplastic Syndrome (MDS)
Condition: Myelodysplastic Syndromes
Intervention: Drug: Daclizumab
7 Completed Characterization of Immunological Profile of Renal Transplant Patients Undergoing Induction Treatment With Thymoglobulin vs. IL-2 Receptor Antagonist Basiliximab
Condition: Renal Transplantation
8 Recruiting Preemptive Therapy of GVHD
Condition: Graft-vs-host Disease
Intervention: Drug: rabbit antithymocyte globulin
9 Completed
Has Results
Anti-Tac for Treatment of Leukemia
Conditions: HTLV-I Infection;   T Cell Leukemia
Intervention: Biological: daclizumab
Condition: Uveitis
Intervention: Drug: Daclizumab (Zenapax)
11 Completed
Has Results
A Phase III Study of Abatacept (BMS-188667) in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Methotrexate;   Drug: Placebo
12 Completed
Has Results
Abatacept With Methotrexate- Phase IIB
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept (BMS-188667);   Drug: Placebo
13 Completed
Has Results
Phase III Study of BMS-188667 (CTLA4Ig) in Patients With Rheumatoid Arthritis Who Are Currently Failing Anti-TNF Therapy or Who Have Failed Anti-TNF Therapy in the Past.
Condition: Rheumatoid Arthritis
Interventions: Drug: Abatacept;   Drug: Placebo
14 Completed Zenapax to Treat Multiple Sclerosis
Condition: Multiple Sclerosis
Intervention: Drug: Zenapax
15 Completed Daclizumab Versus Thymoglobulin in Renal Transplant Recipients With High Immunological Risk
Condition: Renal Transplantation
Interventions: Drug: Thymoglobulin (ATG);   Drug: Daclizumab
16 Completed Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts
Condition: Renal Transplant Rejection
Interventions: Procedure: Kidney transplantation with MSCs infusion;   Procedure: kidney transplantation without MSC infusion
17 Unknown  A Study to Determine Whether Therapy With Daclizumab Will Benefit Patients With Bone Marrow Failure
Conditions: Aplastic Anemia;   Pure Red Cell Aplasia;   Diamond Blackfan Anemia
Interventions: Drug: Daclizumab;   Drug: Daclizumab (Zenapax)
18 Completed
Has Results
Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS
Conditions: Graft vs Host Disease;   Myelodysplastic Syndromes;   Leukemia;   Leukemia, Myeloid;   Leukemia, Myelomonocytic, Chronic;   Leukemia, Lymphocytic;   Lymphoma;   Lymphoma, Mantle-cell;   Lymphoma, Non-Hodgkin;   Hodgkin Disease
Interventions: Drug: RFT5-SMPT-dgA;   Drug: Nexell Isolex system
19 Completed
Has Results
Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia
Condition: Leukemia, Adult T-Cell
Intervention: Biological: Denileukin diftitox (Ontak)
20 Completed
Has Results
Pharmacodynamics, Efficacy and Safety of Basiliximab 40 or 80 mg in Combination With Ciclosporine Microemulsion or Everolimus, in Adult Low Risk de Novo Renal Transplant Recipients (IDEALE Study)
Condition: Renal Transplantation
Interventions: Drug: Simulect®;   Drug: Neoral®;   Drug: Certican®;   Drug: Myfortic®;   Drug: Corticosteroids

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years